{
    "ticker": "SHCR",
    "name": "Shuttle Pharmaceuticals Holdings, Inc.",
    "description": "Shuttle Pharmaceuticals Holdings, Inc. is a biotechnology company focused on the development and commercialization of novel therapeutics for the treatment of cancer and other life-threatening diseases. Founded with the mission to improve patient outcomes through innovative therapies, Shuttle Pharmaceuticals is dedicated to harnessing the power of the body\u2019s immune system to fight cancer. The company specializes in developing proprietary drug candidates that utilize a unique approach to enhance the efficacy of existing cancer treatments. Their lead product candidate, SHCR-002, is designed to be used in combination with standard therapies to improve patient survival rates and quality of life. Additionally, the company is actively engaged in research to identify potential new drug candidates that target various cancer types. Shuttle Pharmaceuticals aims to advance its pipeline through rigorous clinical trials and collaborations with leading research institutions. With a commitment to patient-centered care, Shuttle Pharmaceuticals is poised to make significant contributions to the field of oncology, aiming to provide hope and improved treatment options for patients battling cancer.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Rockville, Maryland, USA",
    "founded": "2019",
    "website": "https://www.shuttlepharma.com",
    "ceo": "Michael J. McGowan",
    "social_media": {
        "twitter": "https://twitter.com/ShuttlePharma",
        "linkedin": "https://www.linkedin.com/company/shuttle-pharmaceuticals"
    },
    "investor_relations": "https://ir.shuttlepharma.com",
    "key_executives": [
        {
            "name": "Michael J. McGowan",
            "position": "CEO"
        },
        {
            "name": "David C. S. Pathak",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "SHCR-002"
            ]
        }
    ],
    "seo": {
        "meta_title": "Shuttle Pharmaceuticals Holdings, Inc. | Innovative Cancer Therapies",
        "meta_description": "Explore Shuttle Pharmaceuticals Holdings, Inc., a biotechnology company dedicated to developing novel cancer treatments. Learn about our innovative therapies and commitment to patient care.",
        "keywords": [
            "Shuttle Pharmaceuticals",
            "Cancer Treatment",
            "Biotechnology",
            "Oncology",
            "SHCR-002"
        ]
    },
    "faq": [
        {
            "question": "What is Shuttle Pharmaceuticals known for?",
            "answer": "Shuttle Pharmaceuticals is known for developing innovative therapeutics for cancer treatment."
        },
        {
            "question": "Who is the CEO of Shuttle Pharmaceuticals?",
            "answer": "Michael J. McGowan is the CEO of Shuttle Pharmaceuticals Holdings, Inc."
        },
        {
            "question": "Where is Shuttle Pharmaceuticals headquartered?",
            "answer": "Shuttle Pharmaceuticals is headquartered in Rockville, Maryland, USA."
        },
        {
            "question": "What is Shuttle Pharmaceuticals' lead product candidate?",
            "answer": "The lead product candidate is SHCR-002, aimed at enhancing cancer treatment efficacy."
        },
        {
            "question": "When was Shuttle Pharmaceuticals founded?",
            "answer": "Shuttle Pharmaceuticals was founded in 2019."
        }
    ],
    "competitors": [
        "AMGN",
        "BMY",
        "JNJ",
        "REGN"
    ],
    "related_stocks": [
        "PFE",
        "MRNA",
        "AZN",
        "GILD"
    ]
}